Steroid Treatment Regimens for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)

Initial Treatment Approach

• For patients with rapidly progressive CTD-ILD or acute respiratory failure, the American Thoracic Society recommends pulse dose IV methylprednisolone (1000 mg daily for 3 days) as first-line treatment, followed by moderate-to-high dose oral prednisone (up to 60 mg daily) with a slow taper over weeks to months 1, 2
• Alternative etiologies, such as infections or lymphoproliferative disorders, must be considered before initiating high-dose steroids, as recommended by the American College of Chest Physicians 2

Disease-Specific Steroid Recommendations

• The American College of Rheumatology strongly recommends against using glucocorticoids as first-line treatment for Systemic Sclerosis-ILD (SSc-ILD) due to risk of scleroderma renal crisis, with a strength of evidence rated as high 3, 4
• The European League Against Rheumatism recommends short-term glucocorticoids as part of initial therapy for Inflammatory Myopathy-ILD (IIM-ILD), Mixed Connective Tissue Disease-ILD (MCTD-ILD), Rheumatoid Arthritis-ILD (RA-ILD), and Sjögren's-ILD, with a strength of evidence rated as moderate 3, 4

Steroid-Sparing Agents

• The American College of Rheumatology conditionally recommends mycophenolate mofetil as the preferred first-line therapy for all types of SARD-ILD, with a strength of evidence rated as moderate 3, 4, 5
• Azathioprine is recommended as a first-line option for myositis-ILD, MCTD-ILD, RA-ILD, and Sjögren's-ILD, with a strength of evidence rated as low 3, 4

Management of Treatment Failure or Disease Progression

• For patients with SSc-ILD progression, the American College of Rheumatology strongly recommends against using long-term glucocorticoids, with a strength of evidence rated as high 4, 5
• For other SARD-ILD progression, the American College of Rheumatology conditionally recommends against using long-term glucocorticoids, with a strength of evidence rated as moderate 4, 5

Monitoring During Treatment

• Daily assessment of respiratory status and oxygen requirements during inpatient treatment is recommended by the American Thoracic Society 1
• Monitor for steroid-related complications, such as hyperglycemia and hypertension, as recommended by the American College of Chest Physicians 1
• Serial pulmonary function tests as clinically indicated are recommended by the American Thoracic Society, with a frequency of every 3-6 months 1

Potential Pitfalls and Caveats

• High-dose steroids in SSc-ILD can trigger scleroderma renal crisis, particularly at prednisone doses >15 mg daily, with a strength of evidence rated as high 3
• Be aware of potential drug-induced lung disease from medications used to treat CTD-ILD, including TNF-alpha inhibitors, sulfasalazine, cyclophosphamide, rituximab, leflunomide, methotrexate, and sulfonamides, as recommended by the American College of Chest Physicians 2
• Pneumocystis jirovecii prophylaxis should be provided when cyclophosphamide is used, as recommended by the American College of Chest Physicians 2

Management of Patients with Interstitial Lung Disease or Autoimmune Diseases Starting Long-Term Steroids

Disease-Specific Contraindications and Treatment

• For patients with systemic sclerosis-ILD, the American College of Rheumatology strongly recommends against using glucocorticoids as first-line therapy due to high risk of scleroderma renal crisis, particularly at prednisone doses >15 mg daily 6, 7

Baseline Evaluation and Monitoring

• The American Thoracic Society recommends obtaining baseline glucose, blood pressure, bone density assessment, and ophthalmologic evaluation for glaucoma/cataracts before initiating steroid therapy, and checking for latent tuberculosis and hepatitis B status before immunosuppression 8
• The American Thoracic Society also recommends assessing thiopurine methyltransferase activity or genotype if azathioprine is being considered as a steroid-sparing agent to prevent life-threatening leukopenia 8

Initial Steroid Dosing Regimens

• For moderate-severe symptomatic ILD (non-SSc), the American College of Chest Physicians recommends standard dosing of prednisone 0.5-1.0 mg/kg daily based on clinical context and disease severity 8

Concurrent Steroid-Sparing Immunosuppression

• The American College of Rheumatology recommends mycophenolate mofetil as the preferred first-line steroid-sparing agent for all SARD-ILD types and should be initiated when long-term steroid use is contemplated 6, 8, 9

Monitoring During Steroid Treatment

• The American College of Chest Physicians recommends monitoring for short-term steroid complications, including glucose intolerance, avascular necrosis, fluid retention, hypertension, myopathy, psychological effects, pancreatitis, truncal obesity, acne, leukocytosis, and ecchymosis 8
• The American College of Chest Physicians also recommends monitoring for long-term steroid complications, including osteoporosis, diabetes, adrenal insufficiency, peptic ulcer disease, hepatic steatosis, glaucoma, cataracts, and hyperlipidemia 8

Management of Disease Progression on Steroids

• For SARD-ILD with progression despite first-line therapy, the American College of Rheumatology conditionally recommends against adding glucocorticoids; for SSc-ILD progression, they strongly recommend against adding glucocorticoids 6, 9
• The American College of Rheumatology recommends considering adding nintedanib for SARD-ILD progression (except SSc-ILD where it may be first-line) 6, 9
• The American College of Rheumatology also recommends considering adding pirfenidone for RA-ILD progression 6, 9

Treatment of CTD-ILD Exacerbation

Immediate Assessment and Stabilization

• For patients with rapidly progressive ILD, the American College of Rheumatology recommends urgent intervention with IV glucocorticoids and upfront combination immunosuppression 10
• For patients with moderate progression, sequential therapy escalation without high-dose steroids is recommended 10

Disease-Specific Acute Management

• The European League Against Rheumatism recommends avoiding glucocorticoids entirely if possible in patients with Systemic Sclerosis-ILD exacerbation due to strong evidence of scleroderma renal crisis risk 10
• For rapidly progressive disease, the American College of Rheumatology recommends using the lowest effective dose of glucocorticoids with close monitoring for renal crisis 10

Definitive Immunosuppression Strategy

• The American College of Rheumatology recommends mycophenolate as the first-line escalation option, starting at 500-1000 mg twice daily, target 1500 mg twice daily 10
• Rituximab is recommended at a dose of 1000 mg IV on days 1 and 15, or 375 mg/m² weekly for 4 weeks 10
• Cyclophosphamide is recommended at a dose of 500-750 mg/m² IV every 4 weeks for 6 months 10, 11

Combination Therapy for Severe Exacerbations

• The American College of Rheumatology recommends using upfront combination therapy (2 agents) rather than monotherapy for rapidly progressive ILD with respiratory failure 10
• Typical combinations include rituximab + cyclophosphamide, or mycophenolate + calcineurin inhibitor 10

Monitoring During Acute Treatment

• The American College of Rheumatology recommends serial testing, including CBC with differential 2-3 weeks after starting immunosuppression, then every 3 months 11
• Liver function tests are recommended with the same frequency 11

Critical Pitfalls to Avoid

• The American College of Rheumatology strongly recommends against using long-term glucocorticoids (>3-6 months) as maintenance therapy due to renal crisis risk in SSc-ILD and lack of efficacy and toxicity in other CTD-ILD 10
• Early immunosuppression is recommended to prevent irreversible fibrosis 12

When to Consider Transplant Referral

• The American College of Rheumatology recommends early referral for lung transplantation evaluation if patients have rapidly progressive ILD despite maximal medical therapy, or presenting with advanced disease (FVC <50% predicted or DLCO <40% predicted) 10
• SSc-ILD patients with progression despite combination therapy should be considered for stem cell transplantation at experienced centers 10